基本數據
| LEI | 549300VLGB1D47GGC642 |
| CIK | 1123494 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Harvard Bioscience, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 2, 2026 |
HARVARD BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN (As Amended) Exhibit 10.2 Appendix A HARVARD BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN (As Amended) The purpose of the Harvard Bioscience, Inc. Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Harvard Bioscience, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, par value $.01 per share (the “Common Stock”) |
|
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 27, 2026 |
Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2025 Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2025 Forward Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “a |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 12, 2026 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2026 Financial Results · First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% · Consolidation of Manufacturing Operations Progressing on Schedule · Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announc |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2026 |
Exhibit 99.1 NASDAQ: HBIO Harvard Bioscience Investor Overview May 2026 Forward - Looking Statements & Non - GAAP Financial Information Forward Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward - looking statements may be identified by the use of words suc |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 17, 2026 |
Exhibit 99.1 NASDAQ: HBIO Harvard Bioscience Investor Overview March 202 6 2 Forward - Looking Statements & Non - GAAP Financial Information Forward Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Secur ities Litigation Reform Act of 1995. Forward - looking statements may be identified by the use of wor |
|
| March 13, 2026 |
Subsidiaries Of Harvard Bioscience, Inc. EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Biochrom Limited United Kingdom CMA Microdialysis Ab Sweden Data Sciences (UK) Mn, Ltd. United Kingdom Data Sciences Eurl France Data Sciences GmbH Germany DSI (Shanghai) Trading Co Ltd. China Harvard Bioscience (Shanghai) Co. Ltd. China Hugo Sachs Elektronik - Harvard Apparatus GmbH Germany Multichannel Systems MCS GmbH Germa |
|
| March 13, 2026 |
EXHIBIT 19 INSIDER TRADING POLICY Revised February 2026 Harvard Bioscience, Inc. and its subsidiaries (collectively, the “Company”) are committed to complying with applicable securities regulations and maintaining the highest ethical standards. We prohibit the trading in Company securities while in possession of material non-public information about the Company. Summary of Key Points ● Trading in |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2026 |
HARVARD BIOSCIENCE, INC. Consolidated Statements Of Operations (In thousands, except per share data) Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results · Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% · Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% · Interim CFO Mark Frost Appointed CFO on Permanent Basis · Introduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 10, 2026 |
HARVARD BIOSCIENCE, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.2 HARVARD BIOSCIENCE, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 6th day of March, 2026 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Mark Frost (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any |
|
| March 10, 2026 |
HARVARD BIOSCIENCE, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 HARVARD BIOSCIENCE, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 6th day of March, 2026 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and John Duke (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any o |
|
| March 6, 2026 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HARVARD BIOSCIENCE, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Harvard Bioscience, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is |
|
| March 6, 2026 |
Harvard Bioscience Announces Reverse Stock Split Exhibit 99.1 Harvard Bioscience Announces Reverse Stock Split - Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 6, 2026 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 10, 2026 |
Exhibit 99.1 Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas - Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance - Expects year over year revenue growth and mid-to high-single-digit EBITDA growth |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 9, 2026 |
Up to 9,500,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-293099 PROSPECTUS Up to 9,500,000 Shares of Common Stock This prospectus relates to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of up to 9,500,000 shares of common stock, par value $0.01 per share (the “Common Stock”), of Harvard Bioscience, Inc. (“Harvard Bioscience” or the “Company”) whi |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| January 30, 2026 |
Exhibit 107 Calculation of Filing Fee Tables S-3 HARVARD BIOSCIENCE INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, $0. |
|
| January 30, 2026 |
As filed with the Securities and Exchange Commission on January 30, 2026 As filed with the Securities and Exchange Commission on January 30, 2026 Registration No: 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 29, 2026 |
Exhibit 99.1 Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth - Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant - Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2 |
|
| January 20, 2026 |
AMENDMENT NO. 2 TO AMENDED AND RESTATED BY-LAWS HARVARD BIOSCIENCE, INC. EXHIBIT 3.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED BY-LAWS OF HARVARD BIOSCIENCE, INC. Article I, Section 5 of the Amended and Restated By-laws of Harvard Bioscience, Inc., is hereby deleted in its entirety and replaced with the following: SECTION 5. Quorum. One-third (33.33%) of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of st |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 12, 2026 |
Exhibit 99.1 HBio Confidential 1 NASDAQ: HBIO HBIO Investor Overview January 202 6 2 Forward Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate, |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 17, 2025 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 17, 2025 (the “Closing Date”) is entered into among Harvard Bioscience, Inc., a Delaware corporation (“Borrower”), each Person party hereto as a guarantor from time to time (collectively, “Guarantors”, and each |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 17, 2025 |
Exhibit 99.1 Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package - Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility - BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., December |
|
| December 17, 2025 |
Exhibit 4.1 THIS WARRANT AND THE SHARES (THE “SECURITIES”) ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURI |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 6, 2025 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2025 Financial Results · Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations · Company Expects to Refinance or Repay the Debt in the Fourth Quarter · Fourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., November |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 9, 2025 |
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors Exhibit 99.1 Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors - Veteran life sciences industry financing leader appointed as new Board member HOLLISTON, Mass., September 9, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): August 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2025 |
Exhibit 10.1 August 8, 2025 Via Email Mark Frost Re: Retention Benefit Opportunity Dear Mark: We are pleased to inform you that, in recognition of your contributions to Harvard Bioscience, Inc. (the “Company”) and your continued employment through March 15, 2026 (the “Retention Date”) you are being offered the opportunity to receive retention benefits (the “Retention Benefits”) on the fol |
|
| August 11, 2025 |
Exhibit 10.1 SIXTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT This SIXTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT (this “Amendment”) is entered into as of August 8, 2025, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), the other Loan Parties party hereto, CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lende |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2025 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2025 Financial Results · Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations · Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline · New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., August 11, 2025 (GLOBE NEWSWIRE) |
|
| July 17, 2025 |
Exhibit 99.1 Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board - Current Board member John Duke to succeed Jim Green as President & CEO - Rob Gagnon and Seth Benson appointed as new Board members - Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, |
|
| July 17, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): July 16, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 17, 2025 |
Employment Agreement between John Duke and the Company dated July 16, 2025 Exhibit 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 16th day of July, 2025 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and John Duke (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, the Company d |
|
| June 27, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorpora |
|
| June 23, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 2, 2025 |
Harvard Bioscience Appoints John Duke to Board of Directors Exhibit 99.1 Harvard Bioscience Appoints John Duke to Board of Directors HOLLISTON, Mass., June 2, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Ead |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 27, 2025 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 Forward Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “a |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 12, 2025 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2025 Financial Results HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as |
|
| April 22, 2025 |
HARVARD BIOSCIENCE, INC. 84 October Hill Road Holliston, Massachusetts 01746 April 21, 2024 Dear Stockholder: You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Harvard Bioscience, Inc. (the Annual Meeting) to be held on Monday, June 2, 2025 at 11:30 a.m. EDT. The Annual Meeting will be held by virtual meeting only. You will not be able to attend the Annual Meeting in |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2025 |
Harvard Bioscience Announces CFO Transition Exhibit 99.1 Harvard Bioscience Announces CFO Transition HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be fil |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2025 |
Exhibit 10.1 April 10, 2025 Via email Mr. Mark Frost Re: Offer of Employment Dear Mark: On behalf of Harvard Bioscience, Inc. (“HBIO” or the “Company”), I am pleased to extend to you an offer of full-time employment as the Company’s Interim Chief Financial Officer and Treasurer, reporting to me. Your principal place of employment will be the Company’s offices in Holliston, Massachusetts. St |
|
| March 14, 2025 |
EXHIBIT 19 INSIDER TRADING POLICY Revised March 2025 Harvard Bioscience, Inc. and its subsidiaries (collectively, the “Company”) are committed to complying with applicable securities regulations and maintaining the highest ethical standards. We prohibit the trading in Company securities while in possession of material non-public information about the Company. Summary of Key Points ● Trading in Com |
|
| March 14, 2025 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Biochrom Limited United Kingdom CMA Microdialysis Ab Sweden Data Sciences (UK) Mn, Ltd. United Kingdom Data Sciences Eurl France Data Sciences GmbH Germany DSI (Shanghai) Trading Co Ltd. China Harvard Bioscience (Shanghai) Co. Ltd. China Hugo Sachs Elektronik - Harvard Apparatus GmbH Germany Multichannel Systems MCS GmbH Germa |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 12, 2025 |
HARVARD BIOSCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical re |
|
| March 12, 2025 |
Exhibit 10.1 FIFTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT This FIFTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT (this “Amendment”) is entered into as of March 10, 2025, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), the other Loan Parties party hereto, CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Len |
|
| March 12, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 26, 2024 |
HARVARD BIOSCIENCE INC. 84 October Hill Road Holliston, Massachusetts 01746-1371 December 26, 2024 HARVARD BIOSCIENCE INC. 84 October Hill Road Holliston, Massachusetts 01746-1371 December 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Margaret Sawicki Re: Harvard Bioscience Inc. Registration Statement on Form S-3 Filed December 6, 2024 File No. 333-283 |
|
| December 12, 2024 |
December 12, 2024 James Green Chief Executive Officer HARVARD BIOSCIENCE INC 84 October Hill Road Holliston, Massachusetts 01746-1371 Re: HARVARD BIOSCIENCE INC Registration Statement on Form S-3 Filed December 6, 2024 File No. |
|
| December 6, 2024 |
As filed with the Securities and Exchange Commission on December 6, 2024 As filed with the Securities and Exchange Commission on December 6, 2024 Registration No. |
|
| December 6, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Harvard Bioscience, Inc. |
|
| November 14, 2024 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP - HARVARD BIOSCIENCE INC Passive Investment SC 13G/A 1 p24-3162sc13g.htm HARVARD BIOSCIENCE INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 7, 2024 |
Harvard Bioscience Announces Third Quarter 2024 Financial Results Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2024 Financial Results HOLLISTON, Mass., November 7, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, “Our third quarter revenues continued to reflect the effects of the challenging market environ |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
Form of Director and Officer Indemnification Agreement Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into this day of 20, by and between Harvard Bioscience, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company) and (“Indemnitee”): WHEREAS, it is essential to the Company that |
|
| August 8, 2024 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2024 Financial Results HOLLISTON, Mass., August 8, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market environment. With the unce |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
Exhibit 10.1 FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of August 6, 2024, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the othe |
|
| August 8, 2024 |
Exhibit 10.4 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Harvard Bioscience, Inc. 2021 Incentive Plan (as am |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 8, 2024 |
Exhibit 10.3 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF TIME-BASED RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended f |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 29, 2024 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Forward Looking Statements Forward-looking statements contained in this Conflict Minerals Report (the “Report”) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which expre |
|
| May 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 14, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2024 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 7, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As ex |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 28, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 3, 2024 | ||
| April 3, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of March 28, 2024 by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the other L |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 19, 2024 |
HBIO / Harvard Bioscience, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) 03/18/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is fi |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States CMA Microdialysis Ab Sweden Data Sciences International, Inc. Delaware, United States Data Sciences (UK) Mn, Ltd. United Kingdom Data Sciences Eurl France Data Sciences GmbH Germany DSI (Shanghai) Trading Co Ltd. China Harvard Bioscience (Shanghai) Co. L |
|
| March 7, 2024 |
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON, Mass., March 7, |
|
| March 7, 2024 |
Harvard Bioscience Inc., Dodd-Frank Clawback Policy EXHIBIT 97 HARVARD BIOSCIENCE, INC. DODD-FRANK CLAWBACK POLICY This document sets forth the Dodd-Frank Clawback Policy (the “Policy”) as adopted by Harvard Bioscience, Inc. (the “Company”) on October 31, 2023. This Policy shall be interpreted to comply with the clawback rules found in 17 C.F.R. §240.10D and the related listing rules of the national securities exchange or national securities associ |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP - HARVARD BIOSCIENCE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / Harvey Partners, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HARVARD BIOSCIENCE, INC. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires F |
|
| February 13, 2024 |
Harvard Apparatus Regenerative Technology, Inc. / HARVARD BIOSCIENCE INC Passive Investment SC 13G/A 1 sc13ga112799hrgn02142024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Harvard Apparatus Regenerative Technology, Inc. (Name of Issuer) Common Stock, $0.01 par value (Ti |
|
| January 26, 2024 |
HBIO / Harvard Bioscience, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us4169061052012624.txt us4169061052012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 22, 2024 |
HBIO / Harvard Bioscience, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) 01/16/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 5, 2024 |
Exhibit 99.1 Jim Green, Chairman , President & CEO January 5, 2024 HBIO Investor Overview Enabling discovery, safety and production of tomorrow’s therapeutics Forward - Looking Statements and Non - GAAP Financial Information Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 7, 2023 |
Harvard Bioscience Announces Third Quarter 2023 Financial Results Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2023 Financial Results · Q3 Revenues of $25.4 million · Q3 Gross Margin of 58.1% · Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million · Continued strong operating cash flow drove debt reduction of $8.3 million through Q3 HOLLISTON, Mass., November 7, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) ( |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 28, 2023 |
HBIO / Harvard Bioscience Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) 08/25/2023 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is fi |
|
| August 16, 2023 |
United States securities and exchange commission logo August 16, 2023 James Green Chief Executive Officer Harvard Bioscience, Inc. |
|
| August 9, 2023 |
August 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Disclosure Review Program 100 F Street, N. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 8, 2023 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2023 Financial Results · Q2 Revenues of $28.8 million · Q2 GAAP operating income $0.8 million, adjusted operating income $3.6 million · Strong H1 operating cash flow drove net debt reduction of $5.4 million HOLLISTON, Mass., August 8, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial re |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 28, 2023 |
United States securities and exchange commission logo July 28, 2023 James Green Chief Executive Officer Harvard Bioscience, Inc. |
|
| June 20, 2023 |
Employment Agreement between Jennifer Cote and the Company dated June 19, 2023 Exhibit 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the date of last signature below (the “Commencement Date”) between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Jennifer Cote (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, t |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 19, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 20, 2023 |
EXHIBIT 99.1 Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice Pre |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Number) Incorporation) 84 October Hill Road, Holliston, MA 01746 (Address of Principal E |
|
| May 30, 2023 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Forward Looking Statements Forward-looking statements contained in this Conflict Minerals Report (the “Report”) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which expre |
|
| May 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 15, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| April 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 25, 2023 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2023 Financial Results • Q1 Revenues of $30 million up 4% over prior year period • Q1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior year • Q1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “C |
|
| April 7, 2023 |
Harvard Bioscience, Inc. 2022 Annual Report Notice of Annual Meeting Proxy Statement Annual Meeting to be held on May 15, 2023 HARVARD BIOSCIENCE, INC. 84 October Hill Road Holliston, Massachusetts 01746-1371 April 5, 2023 Dear Stockholder: You are cordially invited to attend the 2023 Annual Meeting of Stockholders of Harvard Bioscience, Inc. (the “Annual Meeting”) to be held on Monday, May 15, 20 |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 13, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 6, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 9, 2023 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Asys Hitech GmbH Austria Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States CMA Microdialysis Ab Sweden Coulbourn Instruments, LLC Delaware, United States Data Sciences International, Inc. Delaware, United States Data Scienc |
|
| March 9, 2023 |
Harvard Bioscience Announces Fourth Quarter 2022 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2022 Financial Results HOLLISTON, Mass., March 9, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative cur |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 9, 2023 |
Exhibit 10.4 Certain information has been omitted from this document because it is not material and is the type of information the Company treats as private or confidential; such omissions have been marked with the following notation: [OMITTED MATERIAL]. TRADEMARK LICENSE AGREEMENT Effective this 19th day of December 2002, President and Fellows of Harvard College (“Harvard”), a charitable, non-pro |
|
| February 16, 2023 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP Passive Investment SC 13G/A 1 hbio13g.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2022** (Date of Event Which Requires Filing of This Statement) Check the appropriate box to |
|
| February 15, 2023 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * Harvard Bioscience Inc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) November 29, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2023 |
HBIO / Harvard Bioscience, Inc. / Harvey Partners, LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HARVARD BIOSCIENCE, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 13, 2023 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236395d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. 2 )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) Decembe |
|
| February 13, 2023 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SC 13G/A 1 fp0082241-10sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 20 |
|
| January 19, 2023 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (this “Agreement”), dated as of January 18, 2023 (the “Agreement Date”) is entered into by and between Harvard Bioscience, Inc. (the “Company”) and Michael Rossi (“Employee,” and, together with the Company, the “Parties”). All capitalized terms not defined herein shall be given the definition as provided in the employment agre |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 18, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 11, 2023 |
HBIO / Harvard Bioscience, Inc. / Leviticus Partners LP Passive Investment SC 13G/A 1 hbio13ga.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) 01/06/2023 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 3, 2023 |
Letter Agreement between Jennifer Cote and the Company dated December 29, 2022. EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 December 29, 2022 Jennifer Cote Dear Jennifer: I am pleased to offer you the position of Interim Chief Financial Officer and Treasurer of Harvard Bioscience, Inc. (the “Company”), effective as of January 1, 2023, reporting directly to me. In connection with your appointment, we would like to adjust your compensation as follows: 1. Base Salary. Effecti |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorpor |
|
| January 3, 2023 |
Offer Letter between Jennifer Cote and the Company dated April 28, 2022. EX-10.2 3 exh102.htm EXHIBIT 10.2 Exhibit 10.2 Wednesday, April 27, 2022 Revised: Thursday, April 28, 2022 Jennifer S. Cote Holliston, MA 01746 Sent via Email. Dear Jennifer, Harvard Bioscience “HBIO” is pleased to extend to you a full-time offer of employment as Vice President, Finance based on the terms and subject to the conditions described below. I hope that you will find this new position ch |
|
| December 21, 2022 |
HBIO / Harvard Bioscience, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) 12/16/2022 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is fi |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 12, 2022 |
Harvard Bioscience Announces CFO Transition EXHIBIT 99.1 Harvard Bioscience Announces CFO Transition HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced the resignation of Michael Rossi, the Company?s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company?s vice president of global finance, as its interim |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 9, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of November 8, 2022 by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the oth |
|
| November 8, 2022 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2022 Financial Results ?Fighting through challenging times while building the company and new technologies for the future.? HOLLISTON, Mass., November 8, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the third quarter ended September 30, 2022. Jim Green, Chairman and CEO, |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 4, 2022 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2022 Financial Results HOLLISTON, Mass., August 3, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the second quarter ended June 30, 2022. Jim Green, Chairman and CEO, said, "Our second quarter revenues were essentially flat compared to the prior year quarter as growth in |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| July 8, 2022 |
HBIO / Harvard Bioscience, Inc. / BlackRock Inc. Passive Investment us4169061052070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| June 21, 2022 |
Harvard Apparatus Regenerative Technology, Inc. / HARVARD BIOSCIENCE INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Biostage, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 09074M202 (CUSIP Number) June 10, 2022 (Date o |
|
| June 8, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Harvard Bioscience, Inc. |
|
| June 8, 2022 |
As filed with the Securities and Exchange Commission on June 8, 2022 As filed with the Securities and Exchange Commission on June 8, 2022 Registration No. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Number) Incorporation) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 20, 2022 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
|
| May 17, 2022 |
Harvard Bioscience, Inc. Employee Stock Purchase Plan, as amended Appendix A HARVARD BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN (As Amended) The purpose of the Harvard Bioscience, Inc. Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Harvard Bioscience, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, par value $.01 per share (the ?Common Stock?). One Million |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 17, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromto Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 4, 2022 |
Harvard Bioscience Announces First Quarter 2022 Financial Results Exhibit 99.1 Harvard Bioscience Announces First Quarter 2022 Financial Results ? Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds HOLLISTON, Mass., May 4, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the first quarter ended March 31, 2022. Jim Green, Chairman and C |
|
| April 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 27, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 28, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of April 28, 2022 by and among HARVARD BIOSCIENCE, INC. (the ?Borrower?), CITIZENS BANK, N.A. in its capacity as the Administrative Agent (in such capacity, the ?Administrative A |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 11, 2022 |
Form of RSU Award for Directors – 2021 Incentive Plan. Exhibit 10.19 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction AHN Acquisition GmbH Germany Asys Hitech GmbH Austria Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States CMA Microdialysis Ab Sweden Coulbourn Instruments, LLC Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 11, 2022 |
Form of Time-Based RSU Awards Agreement – 2021 Incentive Plan. Exhibit 10.18 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
Form of Performance RSU Award Agreement - 2021 Incentive Plan. Exhibit 10.17 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 8, 2022 |
Harvard Bioscience Announces Fourth Quarter 2021 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2021 Financial Results ? Revenue up 7% year-over-year as sales momentum continues, despite global supply chain headwinds ? Gross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverage HOLLISTON, Mass., March 8, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announc |
|
| February 14, 2022 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. )* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fi |
|
| February 11, 2022 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. 1 )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires |
|
| February 8, 2022 |
HBIO / Harvard Bioscience, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Harvard Bioscience Inc (Name of Issuer) Common Stock (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 3, 2022 |
HBIO / Harvard Bioscience, Inc. / BlackRock Inc. Passive Investment us4169061052020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 28, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (this ?Agreement?), dated as of January 26, 2022 (the ?Agreement Date?) is entered into by and between HARVARD BIOSCIENCE, INC. (the ?Company?) and KEN OLSON (?Employee,? and, together with the Company, the ?Parties?). All capitalized terms not defined herein shall be given the definition as provided in the Parties? September |
|
| January 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromto Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 3, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2021 Financial Results Strong double digit revenue growth, solid margin performance despite global supply chain disruptions ? Revenue up 23% year-over-year as sales momentum continues ? Pre-clinical product revenue up 28% ? Cellular and Molecular Technologies (CMT) product revenue up 19% HOLLISTON, Mass., November 3, 2021 (GLOBE NEWSWIRE) - H |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 3, 2021 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) August 24, 2021 (Date of Event Which Requires Fili |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 5, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2021 Financial Results Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 25% year-over-year as sales momentum continues Cellular and Molecular (CMT) product revenue up 22% Pre-clinical product revenue up 20% Operating margins impacted by higher global supply chain costs HOLLISTON, |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 27, 2021 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 18, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 19, 2021 |
Harvard Bioscience, Inc. 2021 Incentive Plan. Exhibit 10.1 Harvard Bioscience, Inc. 2021 Incentive Plan Article 1 Establishment and Purpose 1.1 Establishment of the Plan. Harvard Bioscience, Inc., a Delaware corporation (the ?Company?), hereby establishes an incentive compensation plan (as amended from time to time, the ?Plan?), as set forth in this document. 1.2 Purpose of the Plan. The purposes of the Plan are to (a) enable the Company and |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 19, 2021 As filed with the Securities and Exchange Commission on May 19, 2021 Registration No. |
|
| May 7, 2021 |
EXHIBIT 32.2 CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned officer of Harvard Bioscience, Inc. (the ?Company?) hereby certifies to his knowledge that the Company?s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the ?Report?) to which this certification is being furnished as an exhibit, as filed with the Securities and Ex |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2021 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2021 Financial Results Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins. ? Revenue up 14% as sales momentum from Q4?20 continues ? Pre-clinical product revenue up 24% ? Operating margin significantly improves year-over-year on GAAP and adjusted basis HOLLISTON, Mass., May |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 17, 2021 |
Subsidiaries Of Harvard Bioscience, Inc. EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Ahn Acquisition Gmbh Germany Asys Hitech Gmbh Austria Biochrom Limited United Kingdom Biochrom Us, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States Cma Microdialysis Ab Sweden Coulbourn Instruments, Llc Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVAR |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 12, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Ahn Acquisition Gmbh Germany Asys Hitech Gmbh Austria Biochrom Limited United Kingdom Biochrom Us, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States Cma Microdialysis Ab Sweden Coulbourn Instruments, Llc Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 10, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2020 Financial Results Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt. • Revenue returns to pre-Covid19 levels on strong CRO/pharma sales • Operating margin increased year-over-year on GAAP and an adjusted basis • New debt facility significantly reduces annual interest |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Harvard Bioscience Inc (Name of Issuer) Common Stock (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2021 |
us4169061052020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) HARVARD BIOSCIENCE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 416906105 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 23, 2020 |
Exhibit 10.3 Execution Version GUARANTEE AGREEMENT among HARVARD BIOSCIENCE, INC. EACH OF THE GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Administrative Agent Dated as of December 22, 2020 TABLE OF CONTENTS Page Article 1. DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Incorporation by Reference 2 Section 1.3 Loan Parties 2 Article 2. GUARA |
|
| December 23, 2020 |
Exhibit 10.1 CREDIT AGREEMENT dated as of December 22, 2020 among HARVARD BIOSCIENCE, INC. as the Borrower, THE LENDERS PARTY HERETO, and CITIZENS BANK, N.A., as Administrative Agent and WELLS FARGO BANK, NATIONAL ASSOCIATION and SILICON VALLEY BANK as Joint Bookrunners, Joint Lead Arrangers and Syndication Agents TABLE OF CONTENTS Page Article 1 Definitions and Rules of Construction 1 Section 1.1 |
|
| December 23, 2020 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT among HARVARD BIOSCIENCE, INC. EACH OF THE GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Administrative Agent Dated as of December 22, 2020 TABLE OF CONTENTS Page Article 1 DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Uniform Commercial Code Terms and Provisions 1 Section 1.3 Other Defined Terms 1 |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 23, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33957 (Commission File Number |
|
| December 23, 2020 |
Harvard Bioscience Announces New Credit Facility EXHIBIT 99.1 Harvard Bioscience Announces New Credit Facility Improves liquidity and operating flexibility Significantly reduces borrowing costs Supports ongoing transformation to profitable growth platform HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 milli |
|
| November 6, 2020 |
As filed with the Securities and Exchange Commission on November 6, 2020 Registration No. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 6, 2020 |
Exhibit 4.7 DEFERRED STOCK AWARD AGREEMENT UNDER THE HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED Name of Grantee: Michael Rossi (the “Grantee”) Grant Date: July 18, 2019 (the “Grant Date”) On the Grant Date, Harvard Bioscience, Inc., a Delaware corporation (including its successors, the “Company”) and the Grantee entered into an employment a |
|
| November 6, 2020 |
Exhibit 4.8 NON-QUALIFIED STOCK OPTION TO PURCHASE SHARES OF COMMON STOCK UNDER THE HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN 111,842 Shares July 18, 2019 (Option Issuance Date) On July 18, 2019, Harvard Bioscience, Inc., a Delaware corporation (including its successors, the “Company”) and Michael Rossi (the “Optionee”) entered into an employment agre |
|
| November 5, 2020 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2020 Financial Results Disciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt • Operating margin up year-over-year on GAAP and adjusted basis • Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening • Generated positive operating cash flow in |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 5, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 10, 2020 |
Harvard Bioscience Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan EXHIBIT 10.1 HARVARD BIOSCIENCE, INC. FOURTH AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN 1) GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Harvard Bioscience, Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Independent Directors and other key persons ( |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 5, 2020 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2020 Financial Results Accelerated cost reduction, cash conservation actions drive increased operating income, reduced net debt · Operating Income up sequentially and year-over-year on both GAAP and adjusted basis · Cost reduction programs offset expected declines in Academic markets · Net Debt reduced by $2.2 million in Q2 HOLLISTON, Mass., |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. R |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 11, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. R |
|
| May 29, 2020 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
